# Metformin Efficacy and Safety in Epileptic Patients

> **NCT05722951** · PHASE3 · COMPLETED · sponsor: **Tanta University** · enrollment: 60 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Levetiracetam &/or sodium valproate
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT05722951
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-18
- **Primary completion:** 2024-06-20
- **Final completion:** 2024-06-20
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05722951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05722951, "Metformin Efficacy and Safety in Epileptic Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05722951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*